SLC5A2 and atrial fibrillation: We further excluded patients that had OHA use <28 days, no follow-up ECG, age <18 years, no ECG prior, during, after OHA use, baseline ECG QTc > 500 ms, atrial fibrillation or atrial flutter within each group, and there were 1,170 patients with ECG on SGLT2 inhibitors and 6,236 patients with non-SGLT2 inhibitors.